Loading...
International Survey for Antiemetics in Hematopoietic Stem Cell Transplantation in the APBMT Centers
Зохиогч
Yakushijin, Kimikazu
Perram, Jacinta
Ho, Aloysius
Farzana, Tasneem
Iida, Hiroatsu
Lee, Jong Wook
Inamoto, Yoshihiro
George, Biju
Wu, Depei
Suzuki, Ritsuro
Behfar, Maryam
Huang, He
Asawapanumas, Thiti
Rowlings, Philip
Poudyal, Bishesh S
Santosa, Damai
Gyi, Aye Aye
Wanitpongpun, Chinadol
Gan, Gin Gin
Iyama, Satoshi
Iqbal, Shahid
Ramzi, Mani
Khadwal, Alka
Kato, Jun
Sim, Joycelyn
Cheng, Jessica
Ma, David
Chua, Yi Xuan
Okamoto, Shinichiro
Iida, Minako
Fuji, Shigeo
Он
2026 оны хоёрдугаар сар
Төрөл
journal article
Journal
Blood cell therapy
Volume
9
Issue
1
Start Page
9
End Page
16
ISSN
2432-7026
Хураангуй
Antiemetic therapy is an essential component of supportive care following hematopoietic stem cell transplantation (HSCT). Chemotherapy and irradiation used in conditioning regimens frequently induce severe nausea and vomiting, which can significantly impair patients' quality of life. Although recent guidelines recommend a triple combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, dexamethasone, and an neurokinin 1 (NK1) receptor antagonist, antiemetic practices vary widely across countries and regions. This study aimed to investigate current antiemetic policies among the Asia-Pacific Blood and Marrow Transplantation (APBMT) centers. A web-based questionnaire survey using SurveyMonkey was distributed via email from the APBMT office between December 7, 2021, and January 21, 2022. The survey addressed antiemetic strategies used in HSCT conditioning regimens. Responses were received from 28 centers across 14 countries. Among the participating centers, 93% reported that physicians were primarily responsible for antiemetic decision-making, with limited involvement from pharmacists or multidisciplinary teams. The most commonly used conditioning regimens for allogeneic HSCT were busulfan and cyclophosphamide (Bu-CY) (72%) and fludarabine and busulfan (Flu-Bu) (62%), whereas high-dose melphalan (83%) and carmustine (BCNU), etoposide, cytarabine arabinoside, and melphalan (BEAM) (69%) were predominant for autologous HSCT. Despite guidelines recommending olanzapine as an additional antiemetic in highly emetogenic chemotherapy, its routine implementation remains limited, even in high-risk settings. Notably, dexamethasone is frequently avoided in allogeneic HSCT, likely due to concerns about its immunosuppressive effects. The incidence of vomiting varied, with 36% of centers reporting rates of 10% or higher, even among those with institutional antiemetic policies. In conclusion, this survey highlighted substantial variation in antiemetic strategies across the APBMT centers. The limited use of olanzapine reflects ongoing concerns regarding its side effects, while the frequent avoidance of dexamethasone in allogeneic HSCT represents a deviation from current guideline recommendations. Given the complexity of HSCT and the varying side effect profiles of antiemetic agents, a multidisciplinary approach to treatment planning, including that of pharmacists and dietitians, could optimize supportive care. Future prospective studies are warranted to evaluate the safety, efficacy, and feasibility of olanzapine- and steroid-sparing antiemetic strategies to improve patient outcomes.
